VRTHF - Veritas Pharma Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.15543
+0.00502 (+3.34%)
As of 3:32PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.15041
Open0.00000
Bid0.00000 x 0
Ask0.00000 x 0
Day's Range0.00000 - 0.00000
52 Week Range
Volume0
Avg. Volume36,069
Market Cap11.78M
Beta-0.95
PE Ratio (TTM)N/A
EPS (TTM)-0.12000
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire18 hours ago

    Veritas Signs MOU with Israeli Cannabis Industry Leader IsCann Group Limited

    VANCOUVER, British Columbia, Aug. 15, 2018-- Veritas Pharma Inc. is pleased to announce that it has signed a Memorandum of Understanding with IsCann Group Limited located in Be'er Tuvya, Israel with the ...

  • GlobeNewswire3 days ago

    Veritas Signs MOU with the Chamber of Commerce, Industry, Services and Tourism Brazil & Puerto Rico

    VANCOUVER, British Columbia, Aug. 13, 2018-- Veritas Pharma Inc. is pleased to announce that it has entered into a Memorandum of Understanding with the Chamber of Commerce, Industry, Services and Tourism ...

  • GlobeNewswire8 days ago

    Frankfurt’s Clearstream Banking Lifts Settlement Restrictions on Securities Active in Medical Cannabis

    VANCOUVER, British Columbia, Aug. 08, 2018-- Veritas Pharma Inc. is pleased to announce that Clearstream Banking, a major central securities depository based in Frankfurt, Germany, which announced on June ...

  • GlobeNewswire20 days ago

    Veritas Pharma Announces Loan to Marapharm and Cancellation of Stock Options

    VANCOUVER, British Columbia, July 27, 2018-- Veritas Pharma Inc. is pleased to announce that effective June 25, 2018, it cancelled a total of 3,272,000 incentive stock options granted under the Company’ ...

  • GlobeNewswirelast month

    Veritas Pharma Signs IP Agreement with UK’s First Medicinal Cannabis Investment Fund

    Veritas Pharma Inc. (CSE:VRT) (VRTHF) (2VP.F), (“Veritas” or the “Company”) is pleased to announce that it has signed an Intellectual Property Sharing Agreement (“Joint IP”) with Sativa Investments PLC (“Sativa”) (NEX:SATI), UK’s first medicinal cannabis investment fund. Veritas through its subsidiary company, Cannevert Therapeutics Ltd., will apply its pharmacological methods on cannabis strain lead selection to assist Sativa’s application to the UK Home Office Drugs Licensing and Compliance Unit for a medicinal cannabis growing license.

  • GlobeNewswire2 months ago

    Veritas Appoints Mr. Filios Theodorou as Its Agent for Cyprus and SEMEA Countries

    Veritas Pharma Inc. (CSE:VRT) (VRTHF) (2VP.F) (“Veritas” or the “Company”) is pleased to announce that Mr. Filios Theodorou has been appointed as its business development agent in Cyprus. Currently, medical cannabis is legal in Cyprus, nonetheless doctors may only prescribe it to patients suffering from specific ailments, typically as a last resort and strictly for palliative care.

  • GlobeNewswire2 months ago

    Veritas Pharma Signs R&D and Medical Cannabis Supply Agreement with Colombian Producer Foliumed S.A.S.

    Veritas Pharma Inc. (CSE:VRT) (VRTHF) (2VP.F), (“Veritas” or the “Company”) is pleased to announce that it has entered into a Memorandum of Understanding (“MOU”) with Colombian medical cannabis company Foliumed S.A.S. (“Foliumed”). Under the terms of the MOU, Veritas and Foliumed will jointly conduct scientific research, undertake product development activities, and commercialize select medical cannabis products with the help of Veritas’ research arm, Cannevert Therapeutics Ltd. (“CTL”).

  • GlobeNewswire3 months ago

    Veritas Pharma Provides Corporate Update on Q2 2018

    Veritas Pharma Inc. (CSE:VRT) (VRTHF) (2VP.F), (“Veritas” or the “Company”) is pleased to provide a corporate update on its achievements, related scientific activities and growth strategies for the second quarter of fiscal 2018. Earlier this year, Veritas Pharma’s subsidiary Cannevert Therapeutics (“CTL”) signed an agreement with Puerto Rico’s Fundación de Investigación (“FDI”) Clinical Research to perform trials of its lead cannabis strain, CTL-X, to target pain.

  • Should You Be Concerned About Veritas Pharma Inc’s (FRA:2VP) Shareholders?
    Simply Wall St.4 months ago

    Should You Be Concerned About Veritas Pharma Inc’s (FRA:2VP) Shareholders?

    In this article, I’m going to take a look at Veritas Pharma Inc’s (DB:2VP) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject amongRead More...

  • PR Newswire6 months ago

    BioCan Technologies Signs Memorandum of Understanding with Veritas Pharma

    CALGARY, Feb. 28, 2018 /CNW/ - BioCan Technologies Inc. ("BioCan" or the "Company") is pleased to announce that it has entered into a Memorandum of Understanding ("MoU") with Veritas Pharma Inc. ("Veritas") (CSE:VRT) (VRTHF) (Frankfurt: 2VP) to collaborate with Veritas on an exclusive basis to undertake further investigations of cannabis strains being developed by the research arm of Veritas, Cannevert Therapeutics Ltd. ("CTL"). The focus will be to optimize the genetics of their cannabis plants for scientific and clinical testing over the next two years.  Pursuant to the MoU, definitive agreements in respect of the transactions contemplated in the MoU are expected to be executed by the parties on or before July 31, 2018. BioCan's CEO, Trevor Peters, stated "We are pleased to be working with Veritas and their scientific teams to develop medically relevant cannabis strains and cannabinoid formulations with optimal therapeutic properties.

  • CNW Group6 months ago

    BioCan Technologies Signs Memorandum of Understanding with Veritas Pharma

    BioCan Technologies Signs Memorandum of Understanding with Veritas Pharma